Salarius Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2024 | 1 | -$53.60 | -$53.60 | -$53.60 |
| Q2 2024 | 1 | -$2.40 | -$2.40 | -$2.40 |
| Q3 2024 | 1 | -$2.31 | -$2.31 | -$2.31 |
| Q1 2025 | 1 | -$2.40 | -$2.40 | -$2.40 |
| Q2 2025 | 1 | -$2.20 | -$2.20 | -$2.20 |
| Q3 2025 | 1 | -$2.24 | -$2.24 | -$2.24 |
| Q4 2025 | 1 | -$2.33 | -$2.33 | -$2.33 |
Salarius Pharmaceuticals, Inc. Earnings Date And Information
Salarius Pharmaceuticals, Inc. last posted its earnings results on Friday, August 9th, 2024. The company reported $-2.37 earnings per share for the quarter, topping analysts' consensus estimates of $-53.6 by $51.23. The company had revenue of 0 for the quarter and had revenue of 0 for the year. Salarius Pharmaceuticals, Inc. has generated $0 earnings per share over the last year ($-0.0038 diluted earnings per share) and currently has a price-to-earnings ratio of -0.35. Salarius Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 20th, 2025 based on prior year's report dates.
Salarius Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2024 | Q3 2024 | -$0.76 | $0 | $0 | ||
| 08/09/2024 | Q2 2024 | -$53.60 | -$2.37 | 51.23 | $0 | $0 |
| 05/13/2024 | Q1 2024 | -$53.60 | -$3.27 | 50.33 | $0 | |
| 03/22/2024 | Q4 2023 | -$8.08 | -$0.22 | 7.86 | $17,892 | |
| 11/09/2023 | Q3 2023 | -$1.07 | -$0.65 | 0.42 | $0 | |
| 08/10/2023 | Q2 2023 | -$1.26 | -$1.43 | -0.17 | $0 | |
| 05/11/2023 | Q1 2023 | -$1.98 | -$2.20 | -0.22 | $0 | |
| 03/27/2023 | Q4 2022 | -$2.07 | -$2.88 | -0.81 | $0 | |
| 11/10/2022 | Q3 2022 | -$2.85 | -$6.38 | -3.53 | $0 | |
| 08/05/2022 | Q2 2022 | -$2.20 | $0 | |||
| 05/12/2022 | Q1 2022 | -$2.25 | -$3.29 | -1.04 | $0 | |
| 03/25/2022 | Q4 2021 | -$2.27 | $-1,840,216 | |||
| 11/04/2021 | Q3 2021 | -$2.25 | -$2.09 | 0.16 | $1.28 M | $0 |
| 08/05/2021 | Q2 2021 | -$1.50 | -$1.72 | -0.22 | $1.37 M | $571,387 |
| 05/12/2021 | Q1 2021 | -$1.25 | -$1.52 | -0.27 | $1.27 M | |
| 03/18/2021 | Q4 2020 | -$2.84 | $1.48 M | |||
| 11/12/2020 | Q3 2020 | -$2.39 | $1.19 M | $1.38 M | ||
| 08/12/2020 | Q2 2020 | -$4.00 | -$3.20 | 0.8 | $1.39 M | $1.24 M |
| 05/14/2020 | Q1 2020 | -$11.00 | -$5.46 | 5.54 | $1.13 M | |
| 03/23/2020 | Q4 2019 | -$14.40 | $1.04 M |
Salarius Pharmaceuticals, Inc. Earnings: Frequently Asked Questions
-
When is Salarius Pharmaceuticals, Inc.'s earnings date?
Salarius Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 20th, 2025 based off last year's report dates.
-
Did Salarius Pharmaceuticals, Inc. beat their earnings estimates last quarter?
In the previous quarter, Salarius Pharmaceuticals, Inc. (:SLRX) reported $-2.37 earnings per share (EPS) to beat the analysts' consensus estimate of $-53.6 by $51.23.
-
How can I listen to Salarius Pharmaceuticals, Inc.'s earnings conference call?
The conference call for Salarius Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
-
How can I read Salarius Pharmaceuticals, Inc.'s conference call transcript?
The conference call transcript for Salarius Pharmaceuticals, Inc.'s latest earnings report can be read online.
-
How much profit does Salarius Pharmaceuticals, Inc. generate each year?
Salarius Pharmaceuticals, Inc. (:SLRX) has a recorded net income of $0. Salarius Pharmaceuticals, Inc. has generated $-0.0038 earnings per share over the last four quarters.
-
What is Salarius Pharmaceuticals, Inc.'s price-to-earnings ratio?
Salarius Pharmaceuticals, Inc. (:SLRX) has a price-to-earnings ratio of -0.35 and price/earnings-to-growth ratio is 0.21.
